MINNEAPOLIS, May 7, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH)
today announced a major publication in the Journal of Prostate Cancer and Prostatic
Diseases entitled, Clinical Utility of the exosome based ExoDx™ Prostate (IntelliScore) EPI
test in men presenting for initial Biopsy with a PSA 2-10ng/mL (link available here). Principal
investigators Dr. Ronald Tutrone, Medical Director of Chesapeake Urology, and Dr. James
McKiernan, Professor of Urology at Columbia University, demonstrated the ExoDx Prostate
test, or EPI, delivered improved patient outcomes over standard of care in a real-world
clinical setting that included 72 urologists, 24 sites and more than 1000 patients. The study
is the first ever prospective, multi-center, randomized prostate biomarker trial with a blinded
control arm conducted in a clinical utility setting, The study was a collaboration between the
largest urology practice in Maryland, Chesapeake Urology, and CareFirst Blue Cross Blue
The EPI test is a urine-based genomic test that helps inform the prostate biopsy decision.
This liquid biopsy test recently received coverage for the VA Healthcare system under the
General Services Administration (GSA) award, received a positive coverage decision from
Medicare, and is included in the National Comprehensive Cancer Network (NCCN)
guidelines for early detection in men for both initial and repeat biopsy. It is performed by
Exosome Diagnostics™, a Bio-Techne brand, in its CLIA, ISO, and NY certified and CAP-accredited
laboratory located in Waltham, Massachusetts. The EPI test is a risk assessment
tool that assists physicians and their patients with determining if a prostate biopsy is needed
when presented with an ambiguous PSA test result, thereby reducing complications from
unnecessary and invasive procedures.
Key findings from the study include:
- When implementing the ExoDx™ Prostate test in a real-world clinical setting, patients demonstrated improved compliance with the physician's recommendation to defer prostate biopsy when the test was negative and go through with a biopsy when the test was positive.
- Twenty-three percent of patients deferred a biopsy due to the EPI test based on the physician-patient shared decision questionnaire.
- In the standard of care setting, many high-grade prostate cancers are missed because not all high-risk men go through with a biopsy.
- Due to improved compliance to proceed to biopsy, physicians detected 30% more cases of clinically significant, or high-grade prostate cancer compared to the standard of care control arm.
These findings can have significant implications for both clinical and economic outcomes.
According to Dr. Ronald Tutrone, "From a clinical perspective, deferring biopsy can help a
patient avoid the undesirable complications from a biopsy, such as pain, hematuria, infection
and potentially hospitalization. Many patients are frightened to undergo biopsy procedure;
however, introducing an EPI result not only improved compliance to proceed to biopsy, but
detected more clinically significant cancers that might have been missed under the standard
of care paradigm."
"This study has important implications from an economic perspective," commented Chuck
Kummeth, President and Chief Executive Officer of Bio-Techne. "Avoiding unnecessary
biopsy procedures represents an estimated savings to the healthcare system of $1,400-
$4,000 per patient, in addition to added costs treating complications. There are economic
consequences to missing high grade prostate cancer as well. Risk stratification tools such
as the ExoDx Prostate test provide the right intervention for the right patient at the right time.
Publication of this study in a leading urology journal confirms our convictions that the ExoDx
Prostate test provides strong clinical utility and economic value to patients, the medical
community and private payors."
A nationwide webinar is scheduled for May 21, 2020 to review the study findings in detail.
More information can be found on the Exosome Diagnostics website at
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Senior Director, Investor Relations & Corporate Development
SOURCE Bio-Techne Corporation